Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics study

BMC Medicine

Research Article

Heiner Boeing¹  Anna Floegel¹  Ulrike Rolle-Kampczyk²  Martin von Bergen³  Wolfgang Otto⁴  Rudolf Kaaks⁵  Theron Johnson⁵  Tilman Kühn⁵  Disorn Sookthai⁵ 

[1] Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Arthur-Scheunert-Allee 114, D-14558, Nuthetal, Germany;Department of Metabolomics, Helmholtz Centre for Environmental Research (UFZ), Permoserstraße 15, D-04318, Leipzig, Germany;Department of Metabolomics, Helmholtz Centre for Environmental Research (UFZ), Permoserstraße 15, D-04318, Leipzig, Germany;Department of Proteomics, Helmholtz Centre for Environmental Research (UFZ), Permoserstraße 15, D-04318, Leipzig, Germany;University of Aalborg, Fredrik Bajers Vej 7H, 9220, Aalborg East, Denmark;Department of Proteomics, Helmholtz Centre for Environmental Research (UFZ), Permoserstraße 15, D-04318, Leipzig, Germany;Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, D-69120, Heidelberg, Germany;

关键词: Metabolomics;    Epidemiology;    Breast cancer;    Prostate cancer;    Colorectal cancer;   

DOI  :  10.1186/s12916-016-0552-3

 received in 2015-10-09, accepted in 2016-01-05,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundFirst metabolomics studies have indicated that metabolic fingerprints from accessible tissues might be useful to better understand the etiological links between metabolism and cancer. However, there is still a lack of prospective metabolomics studies on pre-diagnostic metabolic alterations and cancer risk.MethodsAssociations between pre-diagnostic levels of 120 circulating metabolites (acylcarnitines, amino acids, biogenic amines, phosphatidylcholines, sphingolipids, and hexoses) and the risks of breast, prostate, and colorectal cancer were evaluated by Cox regression analyses using data of a prospective case-cohort study including 835 incident cancer cases.ResultsThe median follow-up duration was 8.3 years among non-cases and 6.5 years among incident cases of cancer. Higher levels of lysophosphatidylcholines (lysoPCs), and especially lysoPC a C18:0, were consistently related to lower risks of breast, prostate, and colorectal cancer, independent of background factors. In contrast, higher levels of phosphatidylcholine PC ae C30:0 were associated with increased cancer risk. There was no heterogeneity in the observed associations by lag time between blood draw and cancer diagnosis.ConclusionChanges in blood lipid composition precede the diagnosis of common malignancies by several years. Considering the consistency of the present results across three cancer types the observed alterations point to a global metabolic shift in phosphatidylcholine metabolism that may drive tumorigenesis.

【 授权许可】

CC BY   
© Kühn et al. 2016